The success of the IPO is seen as a precursor for more big-ticket public floats to come in the next year
The gain was underpinned by the stock's inclusion in the MSCI Standard Index and strong top-line performance in the September quarter
Technical picks from Osho Krishan, senior manager - equity research, Anand Rathi Shares & Stock Brokers
Shares of Orchid Pharma hit 10 per cent lower limit to end at Rs 1,188 on Thursday
Unsustainable debt levels and uncertain business outlook is a common thread among companies
The stock was down 12% to Rs 120 on Friday, its lowest level since May 13, 2014.